Preview

Роль симпатоадреналовой системы и адипокинов в развитии артериальной гипертензии при сахарном диабете 2 типа и ожирении

https://doi.org/10.14341/2071-8713-5050

Полный текст:

Об авторе

А. В. Пашенцева

Россия


Список литературы

1. Аметов А.С. Факторы риска сахарного диабета. Роль ожирения. РМЖ 2003; 11 (27): 22-26.

2. Аметов А.С., Демидова Т.Ю., Галиева О.Р. Ингибиторы АПФ в профилактике и лечении сосудистых осложнений сахарного диабета. Кардиология 2005; 11: 109-112.

3. Балаболкин М.И., Клебанова Е.М. Роль инсулинорезистентности в патогенезе сахарного диабета типа 2. Тер. Архив 2003; 1: 72-77.

4. Терещенко И.В. Лептинорезистентность при сахарном диабете 2 типа. Всероссийский диабетический конгресс. Сборник тезисов. 23-26 мая 2010 г., Москва.

5. Урбанова К.А., Майоров А.Ю., Галстян Г.Р., Ильин А.В., Дедов И.И. Чувствительность к инсулину и адипоцитокины у больных сахарным диабетом 2 типа и предиабетом. Всероссийский диабетический конгресс. Сборник тезисов. 23-26 мая 2010 г., Москва.

6. Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesityrelated hypertension. J. Clin. Invest 2000; 105: 1243-1252.

7. Al-Daghri N, Chetty R, McTernan PG, Al-Rubean K, Al-Attas O, Jones AF, Kumar S Serum resistin is associated with C-reactive protein & LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc. Diabetol 2005 Jul; 5: 10.

8. Alvarez GE, Beske SD., Ballard TP, Davy KP Sympathetic neural activation in visceral obesity. Circulation 2002; 106; 2533-2536.

9. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction. Eur. J. Clin. Invest 2002; 32 (Suppl. 3): 14-23.

10. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance and NIDDM. The Bruneck study. Diabetes 1997; 47; 1643-9.

11. Burnett MS, Devaney JM, Adenika RJ. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J. Clin. Endocrinol. Metab 2006; 91(1): 64-68.

12. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell J.M. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin. Exp. Pharmacol. Physiol 1998 Mar-Apr; 25(3-4): 175-84.

13. Dunstan D, Zimmet P, Welborn T, et al. The rising prevalence of diabetes and impaired glucose tolerance. The Australian diabetes, obesity and lifestyle study. Diabetes Care 2002; 25: 829-34.

14. Engeli S, Sharma AM. Role of adipose tissue for cardiovascular-renal regulation in health and disease. Horm. Metab. Res 2000; 32: 485-499.

15. Frankel DS, Vasan RS, D'Agostino RB Sr, Benjamin EJ, Levy D, Wang TJ, Meigs JB Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J. Am. Coll. Cardiol 2009 Mar; 53(9): 754-62.

16. Fruhbeck G, Jebb SA, Prentice AM. Leptin: physiology and pathophysiology. Clin. Physiol 1998. 18: 399-419.

17. Garvey WT, Maianu L, Zhu Ju-Hong, et al. Evidence for defects in the trafficking and translocation of GLUT4 transporters in skeletal muscle is a cause of human insulin resistance. J. Clin. Invest 1998; 101: 2377-86.

18. Grassi G, Delloro R, Facchini A, et al. Effect of central and peripheral fat distribution on sympathetic and baroreflex function in obese normotensives. J. Hypertens 2004; 22: 2363-2369.

19. Haffner SM, Miettinen H, Mykkanen L, Stern MP. Leptin concentrations are associated with higher proinsulin and insulin concentrations but a lower proinsulin/insulin ratio in non-diabetic subjects. Int. J. Obes 1998; 22: 899-905.

20. Janke J, Engeli S, Gorzelniak K, et al. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes. Res 2002; 10: 1-5.

21. Kunnari A, Ukkola O, Päivänsalo M, Kesäniemi YA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J. Clin. Endocrinol. Metab 2006 Jul; 91(7): 2755-60.

22. Landsberg L, Young JB. Insulin - mediated glucose metabolism in the relationship between dietary intake and sympathetic nervous activity. Int. J. Obes 1985; 9: 63-68.

23. Larsson H, Elmstahl S, Ahren B. Plasma leptin levels correlate to islet function independently of body fat in postmenopausal women. Diabetes 1996; 45: 1580-1584.

24. Lee JH., Chan JL, Yiannakouris N, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J. Clin. Endocrinol. Metab 2003; 88: 4848-4856.

25. Lembo G, Vecchione C, Fratta L, et al. Leptin induces direct vasodilatation through distinct endothelial mechanisms. Diabetes 2000; 49: 293-297.

26. Lonnroth P, Smith U. Adrenergic dependent downregulation of insulin binding in rat adipocytes. Biochem Biophys Res Commun 1983; 112: 972-9.

27. Matsumura K, Abe I, Tsuchihashi T, Fujishima M. Central effects of leptin on cardiovascular and neurohormonal responses in conscious rabbits. Am. J. Physiol. Regul. Integr. Comp. Physiol 2000; 278: R1314-R1320.

28. McTernan PG, McTernan CL, Chetty R, et al. Increased resistin gene and protein expression in human abdominal adipose tissue // J. Clin. Endocrin. Metab 2002; 87: 2407-2410.

29. McTernan CL, McTernan PG, Harte AL, et al. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 36: 46-7.

30. Minn AH, Patterson NB, Pack S, et al. Resistin is expressed in pancreatic islets. Biochem. Biophys. Res. Commun 2003; 310: 641-645.

31. Mojiminiyi OA, Abdella NA. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand. J. Clin. Lab. Invest 2007; 67(2): 215-25.

32. Montani JP, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Obesity 2002; 26 (Suppl. 2): 28-38.

33. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem. Biophys. Res. Commun 2001; 285: 561-564.

34. Nam SY, Kratzsch J, Kim KW, et al. Cerebrospinal fluid and plasma concentrations of leptin, NPY, and alpha-MSH in obese women and their relationship to negative energy balance. J. Clin. Endocrinol. Metab 2001; 86: 4849-4853.

35. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur. J. Endocrinol 2007 Feb; 156(2): 279-84.

36. Osawa H, Doi Y, Makino H, Ninomiya T, Yonemoto K, Kawamura R, Hata J, Tanizaki Y, Iida M, Kiyohara Y. Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study. Cardiovasc. Diabetol 2009 Nov; 18(8): 60.

37. Osei SY, Ahima RS, Krupinski J., et al. Augmentation of renal vasoconstrictor response to norepinephrine and angiotensin II by leptin. Am. J. Hypertens 1999; 12: 32A.

38. Pi-Sunyer FX. Medical hazards of obesity. Ann. Intern. Med 1993; 119: 655-60.

39. Poehlmann ET, Gardner AW, Goran MI, et al. Sympathetic nervous system activity, body fatness, and body distribution in younger and males. J. Appl. Physiol 1995; 78: 802-806.

40. Reaven GM. Syndrome X: 6 years later. J. Int. Med 1994; 236(Suppl 736): 13-22.

41. Saad M.F., Riad-Gabriel M.G., Khan A., et al. Diurnal and ultradian rhythmicity of plasma leptin: effects of gender and adiposity. J. Clin. Endocrin. Metab 1998; 83: 453-459.

42. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31: 409-414.

43. Shigemura N, Ohta R, Kusakabe Y, et al. Leptin modulates behavioral responses to sweet substances by influencing peripheral taste structures. Endocrin 2004; 145: 839-847.

44. Silink M. A United Nations Resolution on Diabetes - The Result of a Joint Effort. US Endocrine Disease 2007; I: 12-14.

45. Stejskal D, Proskova J, Adamovska S, et al. Preliminary experience with resistin assessment in common population. Biomed. Papers 2002; 146(2): 47-49.

46. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12.

47. Takata Y, Osawa H, Kurata M, Kurokawa M, Yamauchi J, Ochi M, Nishida W, Okura T, Higaki J, Makino H. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008 Feb; 51(2): 534-9.

48. Tuck M. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 1992; 19: 167-177.

49. Yura S, Sagawa N, Itoh H, Kakui K, Nuamah MA, Korita D, Takemura M, Fuji S. Resistin is expressed in the human placenta. J. Clin. Endocrinol. Metab 2003; 88: 1394-1397.


Для цитирования:


Пашенцева А.В. Роль симпатоадреналовой системы и адипокинов в развитии артериальной гипертензии при сахарном диабете 2 типа и ожирении. Ожирение и метаболизм. 2012;9(1):14-18. https://doi.org/10.14341/2071-8713-5050

For citation:


Pashentseva A.V. The role of the sympathoadrenal system and adipokines in the development of arterial hypertension in type 2 diabetes mellitus and obesity. Obesity and metabolism. 2012;9(1):14-18. (In Russ.) https://doi.org/10.14341/2071-8713-5050

Просмотров: 62


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)